Joincare Pharmaceutical Group Industry Co.,Ltd.

Informe acción SHSE:600380

Capitalización de mercado: CN¥21.9b

Joincare Pharmaceutical Group IndustryLtd Dirección

Dirección controles de criterios 1/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Xiong Yu

Chief Executive Officer (CEO)

CN¥3.6m

Compensación total

Porcentaje del salario del CEO72.2%
Permanencia del CEOno data
Participación del CEOn/a
Permanencia media de la direcciónsin datos
Promedio de permanencia en la Junta Directivasin datos

Actualizaciones recientes de la dirección

Shareholders Will Probably Hold Off On Increasing Joincare Pharmaceutical Group Industry Co.,Ltd.'s (SHSE:600380) CEO Compensation For The Time Being

May 31
Shareholders Will Probably Hold Off On Increasing Joincare Pharmaceutical Group Industry Co.,Ltd.'s (SHSE:600380) CEO Compensation For The Time Being

Recent updates

Is Joincare Pharmaceutical Group IndustryLtd (SHSE:600380) A Risky Investment?

Nov 17
Is Joincare Pharmaceutical Group IndustryLtd (SHSE:600380) A Risky Investment?

Joincare Pharmaceutical Group Industry Co.,Ltd.'s (SHSE:600380) Business And Shares Still Trailing The Market

Aug 13
Joincare Pharmaceutical Group Industry Co.,Ltd.'s (SHSE:600380) Business And Shares Still Trailing The Market

We Think Joincare Pharmaceutical Group IndustryLtd (SHSE:600380) Can Manage Its Debt With Ease

Jun 23
We Think Joincare Pharmaceutical Group IndustryLtd (SHSE:600380) Can Manage Its Debt With Ease

Shareholders Will Probably Hold Off On Increasing Joincare Pharmaceutical Group Industry Co.,Ltd.'s (SHSE:600380) CEO Compensation For The Time Being

May 31
Shareholders Will Probably Hold Off On Increasing Joincare Pharmaceutical Group Industry Co.,Ltd.'s (SHSE:600380) CEO Compensation For The Time Being

Joincare Pharmaceutical Group IndustryLtd's (SHSE:600380) Conservative Accounting Might Explain Soft Earnings

Apr 09
Joincare Pharmaceutical Group IndustryLtd's (SHSE:600380) Conservative Accounting Might Explain Soft Earnings

Investors Don't See Light At End Of Joincare Pharmaceutical Group Industry Co.,Ltd.'s (SHSE:600380) Tunnel

Mar 04
Investors Don't See Light At End Of Joincare Pharmaceutical Group Industry Co.,Ltd.'s (SHSE:600380) Tunnel

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Xiong Yu en comparación con los beneficios de Joincare Pharmaceutical Group IndustryLtd?
FechaCompensación totalSalarioIngresos de la empresa
Sep 30 2024n/an/a

CN¥1b

Jun 30 2024n/an/a

CN¥1b

Mar 31 2024n/an/a

CN¥1b

Dec 31 2023CN¥4mCN¥3m

CN¥1b

Sep 30 2023n/an/a

CN¥1b

Jun 30 2023n/an/a

CN¥2b

Mar 31 2023n/an/a

CN¥2b

Dec 31 2022CN¥4mCN¥3m

CN¥2b

Sep 30 2022n/an/a

CN¥1b

Jun 30 2022n/an/a

CN¥1b

Mar 31 2022n/an/a

CN¥1b

Dec 31 2021CN¥3mCN¥2m

CN¥1b

Compensación vs. Mercado: La compensación total de Xiong($USD497.14K) está por encima de la media de empresas de tamaño similar en el mercado CN ($USD209.90K).

Compensación vs. Ingresos: La compensación de Xiong ha sido consistente con los resultados de la empresa en el último año.


CEO

Xiong Yu (63 yo)

no data

Permanencia

CN¥3,600,000

Compensación

Mr. Xiong Yu serves as Sichuan Biokin Pharmaceutical Co.,Ltd. since September 17, 2019. He served as Non-Executive Director of Livzon Pharmaceutical Group Inc. since June 30, 2020 until October 14, 2024.H...